Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT News, features, and commentary about cancer-related issues Jul 05, 2024
Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma Joseph Mikhael, MD, leads a discussion on the DREAMM-7 and DREAMM-8 trials Jul 05, 2024 video
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma Joseph Mikhael, MD, leads a discussion on the subgroup analysis of CARTITUDE-4 Jun 27, 2024 video
Real-World Analysis Identifies Meds Tied to Higher Risk of Liver Injury Case reports may not be as reliable, researchers say Jun 25, 2024
Using MRD Status to Deescalate Multiple Myeloma Therapy Joseph Mikhael, MD, leads a discussion on the findings of the MRD2STOP study Jun 20, 2024 video
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma Joseph Mikhael, MD, leads a roundtable discussion on two positive phase III trials from ASCO Jun 14, 2024 video
Adding Isatuximab to Standard Backbone Improves Outcomes in Multiple Myeloma Two trials show positive outcomes Jun 04, 2024
Industry Clinic โข Ad Insights What Will It Take to Deliver Both Health & Care in Oncology? Jun 04, 2024
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma Second belantamab mafodotin-containing triplet to show potency in this setting Jun 02, 2024
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise News, features, and commentary about cancer-related issues May 10, 2024
Ending Oncology's Toxic Relationship With High Chemotherapy Doses Optimizing doses can improve patient outcomes and lower costs May 10, 2024
Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCT ORR reaches 90% with isatuximab plus KRd in newly diagnosed disease Apr 26, 2024
FDA Approves Earlier Use of CAR-T Products for Myeloma Carvykti and Abecma move to second- and third-line, respectively Apr 08, 2024
High Response Rate in R/R Multiple Myeloma With Bispecific Antibody ORR of 71% that deepened over time and favorable safety profile with linvoseltamab Apr 08, 2024
Chemo and Heart Disease; Flawed Lung Cancer Screening; New Vax Recommendations News, features, and commentary about cancer-related issues Mar 29, 2024
FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myeloma Cilta-cel, ide-cel win support despite concerns about early mortality risk Mar 16, 2024
Early Death Risk Muddies Risk-Benefit Assessment of CAR-T Therapies for Myeloma FDA advisory panel to weigh the evidence for cilta-cel, ide-cel in day-long meeting Mar 14, 2024
A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu News, features, and commentary about cancer-related issues Mar 07, 2024
Toxic Gas That Sterilizes Medical Devices Prompts Safety Rule Update The EPA is set to take action after public outcry Mar 03, 2024
Taking Control of the Cancer Journey Kathy Giusti gives patients and healthcare workers advice for navigating cancer treatment Mar 02, 2024 podcast
Amy Schumer's Diagnosis; FDA Yanks Cancer Drug; Nursing Student Murdered Health news and commentary from around the Web gathered by ทฌวัษ็ว๘ staff Feb 26, 2024
Transforming Shots Into Pills; 'Tip of the Iceberg' for TILs? Food Additives Warning News, features, and commentary about cancer-related issues Feb 23, 2024
Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma No PFS benefit from adding the monoclonal antibody to standard therapy Feb 20, 2024
Pulled Myeloma Drug May Have a Role in Treating the Disease After All Belantamab mafodotin boosts PFS by nearly 2 years when combined with bortezomib, dexamethasone Feb 07, 2024
When a Revolutionary Cancer Treatment Causes Cancer The potential benefits of CAR T-cell therapies still far outweigh the risks Jan 27, 2024
How Can Cancer Risk Be Cut in Communities Exposed to Toxins? Group outlines plan to bring the latest testing and treatment to medically underserved minorities Jan 25, 2024
CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning Post-treatment cases grow to 22 since products' initial approvals Jan 24, 2024
FDA Calls for New Boxed Warning on All CAR-T Products Most serious warning would alert patients, providers on potential risk for secondary malignancies Jan 23, 2024
Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma Subcutaneous administration of the anti-CD38 antibody also made for easier dosing Jan 04, 2024
Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma? Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease Dec 21, 2023 video
Why Some Myeloma Patients Refuse Stem Cell Transplant Study shows the various factors behind refusal of autologous stem cell transplantation Dec 15, 2023 video
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials Survival 75% worse compared with outcomes seen in registrational studies Dec 10, 2023
Let's Talk Drug Prices; Restoring the Sense of Touch; Learning From Tumors in a Dish News, features, and commentary about cancer-related issues Dec 01, 2023
FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy Applies to all approved therapies, but benefits still outweigh risks, agency says Nov 28, 2023
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh News, features, and commentary about cancer-related issues Nov 10, 2023
Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia News, features, and commentary about cancer-related issues Nov 03, 2023
Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd Oct 19, 2023
Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment News, features, and commentary about cancer-related issues Oct 19, 2023
Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines; Struggling to Live News, features, and commentary about cancer-related issues Oct 06, 2023
